Hitachi Chemical Advanced Therapeutics Solutions, LLC
Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), is a wholly owned subsidiary of Hitachi Chemical Company, Ltd. representing its Regenerative Medicine Business Sector. Its vision is a world in which transformative cell-based therapeutics are accessible to all, and its mission is to provide its clients with high-quality, scalable, innovative, reliable and cost-efficient manufacturing platforms and services to advance commercialization of cellular therapies.
The PCT Service Platform
HCATS offers PCT, a cell therapy manufacturing and development service platform, leveraging nearly two decades of experience exclusively focused on the cell therapy industry. The PCT service platform includes contract development and manufacturing organization (CDMO) services, at current Good Manufacturing Practices (cGMP) standards, including clinical and commercial manufacturing, manufacturing development, and technology development. Visit www.pctcelltherapy.com for more information.
Our cGMP Facilities
HCATS operates cGMP manufacturing facilities in the U.S. in Allendale, New Jersey (headquarters) and Mountain View, California. A facility in Yokohama, Japan is now under construction and another U.S. facility is planned for Allendale. European operations will begin in 2018. All facilities operate on our global, harmonized PCT service platform.